Cell and gene therapy logistics market seen topping $3B by 2030

The market for cell and gene therapy supply chain and logistics is projected to exceed $3 billion by 2030, driven by growing demand for cold chain, real-time tracking and digital orchestration tools. North America is expected to remain the largest region, while the U.S. leads country-level growth.

Why it matters: - Cell and gene therapies depend on tightly controlled logistics, so growth in this market reflects how quickly advanced treatments are moving into routine commercialization. - The market is projected to surpass $3 billion in 2030, a small share of the broader healthcare services and other services and products markets, but a critical one for personalized medicine delivery. - Demand is rising for systems that reduce therapy delays, protect product viability and improve chain-of-identity tracking.

What happened: - The Business Research Company published a 2026 market report on global cell and gene therapy supply chain and logistics, with forecasts running through 2035. - The report estimates the market will grow at a 12% CAGR through 2030. - North America is projected to be the largest region in 2030, with a market value of $1.06 billion. - The U.S. is expected to be the largest country market in 2030, valued at $0.98 billion. - The cell orchestration platform segment is forecast to be the largest software category in 2030, accounting for 25% of the market, or about $1 billion.

The details: - North America’s market is expected to rise from $0.63 billion in 2025 to $1.06 billion in 2030, a CAGR of 11%. - U.S. market value is projected to increase from $0.59 billion in 2025 to $0.98 billion in 2030, also at 11% CAGR. - The report says North America’s growth is supported by commercialization of advanced therapies, cold chain investment, temperature-controlled logistics, cryogenic transport, digital monitoring and a dense base of biotech, CDMOs and logistics providers. - U.S. growth is tied to approved personalized therapies, more regenerative medicine trials, real-time tracking, chain-of-identity systems and expanded specialized healthcare logistics networks. - The software market includes cell orchestration platforms, enterprise manufacturing systems, inventory management systems, laboratory information management systems, logistics management systems, patient management systems, quality management systems and tracking and tracing systems. - The deployment market is split between cloud-based and on-premises solutions. - The component market includes cryogenic shippers, cryogenic storage freezers, ultra-low freezers, cold chain management systems, shipment, storage medium, cryogenic packout kits and other components. - The application market covers donor eligibility assessment, sample collection, manufacturing, logistics, patient verification and treatment follow-up. - End users include biobanks, cell therapy labs, hospitals, research institutes and commercial organizations. - The report says the cell orchestration platform segment will be supported by workflow complexity, integrated scheduling, chain-of-custody visibility, faster turnaround needs and automation. - The report identifies the biggest growth opportunities in cell orchestration, enterprise manufacturing, inventory management, laboratory information management, logistics management, patient management, quality management and tracking and tracing systems. - Those segments are projected to add more than $1.1 billion in combined value by 2030. - Over the next five years, the report projects growth of $0.3 billion for cell orchestration platforms, $0.1 billion each for enterprise manufacturing, inventory management, laboratory information management, logistics management, patient management and quality management, and $0.2 billion for tracking and tracing systems. - The report links overall market growth to customer experience, e-commerce and digital transformation, and data-driven operational strategies. - It estimates seamless customer experience will contribute about 2.5% annual growth, digital transformation about 2.3%, and data-driven retail strategies about 2.1%. - The Business Research Company says its 2026 reports include market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, market hotspot infographics, key technology analysis and updated graphics and tables. - The company says it has published more than 30,000 reports across 27 industries and 60 geographies and draws on 1,500,000 datasets. - Request a free sample of the report - Access the detailed market report

Between the lines: - The forecast suggests the biggest near-term value is not in therapy development alone, but in the infrastructure that moves, stores and tracks these therapies safely. - The emphasis on orchestration, tracking and digital monitoring points to a market where software and workflow control matter as much as physical cold chain assets. - The regional and segment breakdown shows the U.S. and North America remain the center of gravity for commercialization and logistics innovation.

What's next: - Growth is expected to continue as more advanced therapies move through clinical and commercial pipelines. - Spending should keep shifting toward connected logistics platforms, cryogenic handling and compliance-focused automation. - The fastest gains are likely to come from systems that improve visibility, reduce errors and support personalized treatment timelines.

The bottom line: - Cell and gene therapy logistics is becoming a bigger, more software-driven market as personalized medicine scales and supply chains get more complex.